Vietnamese crab exporter

US firm Moderna testing vaccine says can produce limited quantity by fall of 2020

The company is developing a Covid-19 vaccine named mRNA-1273, which is based on the work done by researchers from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) in the USA.

Advertisement
US firm Moderna testing vaccine says can produce limited quantity by fall of 2020
Several pharma companies are testing vaccines for coronavirus. (AP photo)

The US-based pharmaceutical company Moderna, which has been testing a vaccine for Covid-19 on Monday filed a disclosure report before the US Securities and Exchange Commission, suggesting that the company will be able to produce a limited series vaccine against Covid-19 in the fall of 2020.

The filling has quoted a statement given by Moderna CEO Stephane Bancel to a representative of Goldman Sachs where he has said, "While a commercially-available vaccine is not likely to be available for at least 12-18 months, it is possible that under emergency use, a vaccine could be available to some people, possibly including healthcare professionals, in the fall of 2020."

advertisement

The company is developing a Covid-19 vaccine named mRNA-1273, which is based on the work done by researchers from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) in the USA.

The Phase 1 study of the vaccine is in motion under which the first participant was given a dose on March 16, 2020.

The scientists and doctors are currently evaluating the safety and immunogenicity of the doses. Under the program, a healthy person will undergo two-dose vaccination schedule scheduled 28 days apart.

According to the filling "a total of 45 healthy adults will be enrolled in this study".

Participants will be followed through 12 months before the vaccine is commercially available in the market.

Meanwhile, the number of positive Covid-19 cases has crossed 3,50,000 globally while the death toll has crossed 16,000.

Also Read | In global fight against coronavirus, over 1.5 billion told: Stay home
Also Read | Airborne spread of Covid-19 not reported so far: WHO official
Also Watch | What are the challenges to deal with coronavirus spread in India | Experts debate

Ankit Kumar

Ankit Kumar (a.k.a. Ankiit Koomar) – Editor, Open-Source Investigations, India Today TV & Aaj Tak

Ankit Kumar is the Editor of Open-Source Investigations (OSINT) and Visual Investigations at India Today TV and Aaj Tak.  A two-time JournalismAI fellow with the London School of Economics (LSE), Ankit’s work lies at the intersection of investigative journalism and emerging digital tools as well as use of Artificial Intelligence (AI) in journalism. He has pioneered South Asia’s first dedicated OSINT journalism team, bringing cutting-edge technology into the newsroom.

His investigative reports have made national headlines and even been debated in the Indian Parliament. He was the first journalist to uncover the common link between middlemen networks in two of India’s most controversial defence deals—the VVIP AgustaWestland Chopper Deal and the Rafale Jet Deal . His reports have been frequently cited by both the Prime Minister and opposition leaders, shaping public discourse on key national security matters.

Ankit’s deep-dive investigation into the Indian Air Force’s Balakot Airstrikes was the first to feature key eyewitness accounts from the ground. 

Following his report, a UK-based dubious news portal that propagated false claims of large-scale EVM fraud in India was shut down. His stories cover a wide spectrum—from finance, business, and cybersecurity to disinformation, artificial intelligence (AI), and emerging global threats.

His work has been recognized globally, with the Global Investigative Journalism Network (GIJN) listing his reporting among the year’s top investigative stories.

🔹 Connect with him: @AnkiitKoomar on X / LinkedIn
📩 Email: [email protected]

 

READ MORE